The label documentation for the agent in question is ambiguous on exactly this point.
I have read the primary source rather than the summary, which has left me with more questions.
I understand the headline. I do not understand the footnotes, and the footnotes look important.
What would I need in addition before this supported a decision?
SUSTAIN-6 would have written it into the protocol, and the wording is the part that matters. Escalation protocols in this class generally permit a delay at the current level, sometimes a single step down with a later re-attempt, and count a participant as remaining in the arm throughout. That is analytically important: an intention-to-treat analysis keeps them at their randomised assignment regardless of the dose they were actually taking, so the "top dose" arm contains people who never reached the top dose. Find the protocol amendment history as well as the paper, because tolerability rules are among the things most often revised mid-programme, and dose-escalation decisions are made under supervision — nothing here is medical advice.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
| Agent | Start | Step interval | Maintenance range | Max studied |
|---|---|---|---|---|
| Semaglutide (weight management) | 0.25 mg/wk | 4 weeks | 1.7–2.4 mg/wk | 2.4 mg/wk |
| Semaglutide (T2DM) | 0.25 mg/wk | 4 weeks | 0.5–2.0 mg/wk | 2.0 mg/wk |
| Tirzepatide | 2.5 mg/wk | 4 weeks | 5–15 mg/wk | 15 mg/wk |
| Liraglutide (weight management) | 0.6 mg/day | 1 week | 3.0 mg/day | 3.0 mg/day |
| Oral semaglutide | 3 mg/day | 4 weeks | 7–14 mg/day | 50 mg/day (trial) |
Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.
Specifically, escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
Hold rather than escalate while symptoms are active. Always.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Stated carefully, titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Nothing here is medical advice, and research-use compounds are not approved for human use.
The top of the schedule is not the target. The working dose is.
Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
It helps to be literal here: for an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Stepping back is a normal adjustment, not a failure.
Put another way, this is the single most consequential controllable variable in the whole experience, and people routinely rush it.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Four half-lives between steps, minimum. Work it out for your agent.
Escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Slower costs time and nothing else. The ceiling is the same.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.